Rep. Laurel M. Lee Purchases Shares of Pfizer Inc. (NYSE:PFE)

Representative Laurel M. Lee (R-Florida) recently bought shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on November 21st, the Representative disclosed that they had bought between $15,001 and $50,000 in Pfizer stock on October 21st.

Representative Laurel M. Lee also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of GE Vernova (NYSE:GEV) on 11/8/2024.
• Purchased $15,001 – $50,000 in shares of Apple (NASDAQ:AAPL) on 10/7/2024.
• Purchased $50,001 – $100,000 in shares of JPMorgan Chase & Co. (NYSE:JPM) on 9/10/2024.

Pfizer Price Performance

NYSE PFE opened at $25.65 on Friday. The stock has a market capitalization of $145.36 billion, a price-to-earnings ratio of 34.66, a PEG ratio of 0.80 and a beta of 0.67. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s fifty day moving average price is $28.21 and its 200-day moving average price is $28.57.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to the consensus estimate of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.17) earnings per share. On average, equities analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 dividend on an annualized basis and a yield of 6.55%. Pfizer’s dividend payout ratio is presently 227.03%.

Analyst Upgrades and Downgrades

A number of analysts have commented on PFE shares. Barclays upped their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research began coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective for the company. UBS Group lifted their target price on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Citigroup began coverage on Pfizer in a research report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $32.92.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. purchased a new position in Pfizer during the 1st quarter valued at approximately $315,000. Edgestream Partners L.P. bought a new stake in Pfizer in the first quarter worth $243,000. EP Wealth Advisors LLC raised its stake in Pfizer by 0.9% during the first quarter. EP Wealth Advisors LLC now owns 336,062 shares of the biopharmaceutical company’s stock valued at $9,326,000 after purchasing an additional 2,864 shares in the last quarter. Stonebridge Capital Advisors LLC lifted its position in Pfizer by 35.2% during the first quarter. Stonebridge Capital Advisors LLC now owns 26,586 shares of the biopharmaceutical company’s stock valued at $738,000 after purchasing an additional 6,921 shares during the last quarter. Finally, Gamco Investors INC. ET AL grew its stake in shares of Pfizer by 123.9% in the 1st quarter. Gamco Investors INC. ET AL now owns 533,251 shares of the biopharmaceutical company’s stock worth $14,798,000 after buying an additional 295,139 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Transactions at Pfizer

In related news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.06% of the company’s stock.

About Representative Lee

Laurel Lee (Republican Party) is a member of the U.S. House, representing Florida’s 15th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2025. Lee (Republican Party) is running for re-election to the U.S. House to represent Florida’s 15th Congressional District. She declared candidacy for the Republican primary scheduled on August 20, 2024. Gov. Ron DeSantis (R) appointed Lee to serve as the Florida Secretary of State on January 28, 2019, after the resignation of Michael Ertel on January 24. Lee resigned on May 16, 2022. Lee was a judge of the 13th Judicial Circuit Court in Florida from 2013 to 2019. She was appointed to the court by Gov. Rick Scott (R) in May 2013. She was elected to the position in 2014. Laurel Lee earned undergraduate and law degrees from the University of Florida. Lee’s career experience includes working as an attorney with Carlton Fields, P.A., an assistant federal public defender and assistant U.S. attorney with the United States District Court for the Middle District of Florida, and a law clerk to James S. Moody on the United States District Court for the Middle District of Florida.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.